巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Capricor Therapeutics

    CAPR
    5.970
    0.190
    3.29%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Capricor Therapeutics - 延遲價格・最後更新於 28/09 8:28
    最高位
    6.080
    最低位
    5.800
    開市價
    --
    前收市價
    5.780
    成交量(千)
    5.26
    成交額(百萬)
    0.31
    買入
    4.980
    賣出
    7.060
    每手股數
    --
    市值(百萬)
    145.35
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    6.210 - 2.560
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Capricor Therapeutics
    證券代碼
    CAPR.US
    所屬板塊
    Biotechnology
    公司業務
    Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
    發行量
    24298406
    公司總部
    10865 Road to the Cure, Suite 150
    公司網址
    https://www.capricor.com
    公司電話
    +1 310 358-3200
    暫無內容

    關於

    Capricor Therapeutics(CAPR.US)所屬的行業板塊為Biotechnology。
    Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
    詳細公司背景可參考: https://www.capricor.com